As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg

'Africa at risk of continent-wide Ebola crisis, health chief warns' - Semafor

NanoViricides Files Prospectus For Offering $2.375M Common Stock

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups

A drug being tested for Ebola showed no harmful effects in a young-mouse safety study

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well

NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

An Ebola trial in Congo is dosing patients with a drug that dissolves in the mouth.